Jul 20, 2020
Lyfaquin®, a first-in-class resuscitative agent for patients with excessive blood loss, to be launched in India
May 14, 2020
Marketing authorization received for Lyfaquin(TM) (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency
Apr 27, 2020
Sovateltide significantly (p=0.0157) improved clinical outcome (modified Rankin Scale) in patients with acute cerebral ischemic stroke when compared to standard of care
Feb 07, 2020
Successful meeting with USFDA to file an IND application to initiate phase III clinical trial of centhaquine in patients with hypovolemic shock
Nov 23, 2019
Dosing of first patient in phase 3 pivotal study of sovateltide (PMZ-1620), a first-in-class investigational product, for acute cerebral ischemic stroke
Oct 28, 2019
Pharmazz submits application for marketing authorization of centhaquine (PMZ-2010), a first-in-class investigational product, for patients with hypovolemic shock
Sep 30, 2019
Sovateltide (PMZ-1620), an Endothelin-B receptor Agonist, has the potential to be a first-in-class neuronal progenitor cell therapeutics
Jul 18, 2019
PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
Feb 07, 2019
Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
Nov 12, 2018
Phase 2 Results on Efficacy of PMZ-2010 (Centhaquin) in Patients with Hypovolemic Shock Presented at AHA Scientific Sessions 2018
May 17, 2018
Clinical phase II results indicate that PMZ-2010 (centhaquin) is a novel highly effective resuscitative agent for hypovolemic shock
Mar 30, 2018
Notice of allowance issued for two Canadian patent applications and US Congressman Bill Foster visits Midwestern University
Jan 11, 2018
Issuance of patent and initiation of a study to evaluate PMZ-1620 in dogs with degenerative myelopathy, a disease similar to human amyotrophic lateral sclerosis (ALS)
Oct 18, 2017
Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management